SCHEMBL5776654

SCHEMBL5776654

CN(Cc1csc(C=O)n1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
USP30 Q70CQ3 2/20 0.35
HDAC1 Q13547 5/20 0.35
HDAC6 Q9UBN7 5/20 0.35
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
ENPP2 Q13822 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16742778 0.82 ENPP2 (0.36) HDAC1HDAC6ENPP2MEN1KMT2A
SCHEMBL1711643 0.72
SCHEMBL5776659 0.69 MAPT (0.48) NPC1RAB9ASMN1; SMN2HDAC1HDAC6
SCHEMBL4697461 0.68 CCR4 (0.39) HDAC1HDAC6
SCHEMBL28315930 0.66 HDAC1 (0.31) HDAC1HDAC6
SCHEMBL27293724 0.65 L3MBTL1 (0.46) MEN1KMT2AL3MBTL1
SCHEMBL17716412 0.65 MAPT (0.49) NPC1RAB9ASMN1; SMN2L3MBTL1HSD17B10
SCHEMBL16095606 0.64 GABRA5 (0.47) NPC1RAB9ASMN1; SMN2USP30MEN1
SCHEMBL19211479 0.64 PARP1 (0.40) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL15492369 0.64 L3MBTL1 (0.44) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT NPC1 952/4885RAB9A 3127/4885SMN1; SMN2 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.